Clinical efficacy and safety of sitafloxacin for refractory urinary tract infection

Takehiro Iwata0 个研究点目标入组 92 人开始时间: 2021年2月2日最近更新: 2023年10月17日

试验速览

暂无简介。

•Aged 20 years and over and fever >=37.5 degree centigrade with any urinary tract infection symptoms, such as costovertebral angel tenderness, micturition pain, urinary frequency, urgency or lower abdominal pain with pyuria. Pyuria was defined as: >=10 white blood cells (WBCs)/mL counted by flow cytometric analysis; >=10 WBCs/mm3 counted by counting chamber or a positive leucocyte esterase result using urine test paper with uncentrifuged urine; or .5 WBCs/high-power field in the sediment of centrifuged urine.
•The patints who were diagnosed as complicated cystitis or recurrent cystitis or pyelonephritis or prostatitis or epididymitis.

•Patients who had a previous episode of quinolone hypersensitivity, who had allergic asthma or hives; immunosuppression; spastic diseases such as epilepsy; myasthenia gravis; aortic dissection; current pregnancy; renal failure, who are or will be pregnant.
•Viable cell count before start of medication <10 ^ 5 CFU / mL.
•Patients who have urethral catheterization or intermittent catheterization.
•Patients who were judged as ineligible for this study by the investigators because of low compliance.

发起方

Takehiro Iwata